Gilead Sciences, Inc. (NASDAQ:GILD) Forecasted to Earn FY2026 Earnings of $7.45 Per Share

Gilead Sciences, Inc. (NASDAQ:GILD) – Research analysts at Zacks Research boosted their FY2026 earnings estimates for shares of Gilead Sciences in a report released on Wednesday, September 4th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earnings of $7.45 per share for the year, up from their prior estimate of $7.42. The consensus estimate for Gilead Sciences’ current full-year earnings is $3.78 per share.

A number of other research firms also recently weighed in on GILD. Robert W. Baird reaffirmed a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research report on Thursday, June 20th. Raymond James upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price for the company in a report on Monday, July 8th. BMO Capital Markets raised their price objective on Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Finally, Royal Bank of Canada upped their price target on shares of Gilead Sciences from $72.00 to $74.00 and gave the stock a “sector perform” rating in a research note on Wednesday, September 4th. Twelve research analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.25.

Gilead Sciences Price Performance

Shares of GILD stock opened at $79.17 on Monday. The business’s fifty day moving average is $74.27 and its 200 day moving average is $70.59. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. The stock has a market cap of $98.57 billion, a price-to-earnings ratio of 219.92, a PEG ratio of 2.73 and a beta of 0.18. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The company had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Norges Bank purchased a new stake in shares of Gilead Sciences in the fourth quarter worth $1,301,624,000. The Manufacturers Life Insurance Company increased its stake in Gilead Sciences by 78.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 7,632,000 shares of the biopharmaceutical company’s stock worth $618,268,000 after buying an additional 3,362,505 shares in the last quarter. Vanguard Group Inc. raised its holdings in Gilead Sciences by 2.6% during the first quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock valued at $8,404,161,000 after acquiring an additional 2,910,147 shares during the period. Wellington Management Group LLP lifted its position in shares of Gilead Sciences by 14.4% in the fourth quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock valued at $1,509,227,000 after acquiring an additional 2,350,550 shares in the last quarter. Finally, Swedbank AB bought a new position in shares of Gilead Sciences in the first quarter worth about $134,489,000. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares in the company, valued at approximately $8,506,146.42. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the transaction, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.89%. The ex-dividend date of this dividend is Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.